Resminostat

Chemical Compound
Identifiers
CAS Number
PubChem CID
ChemSpider ID
UNII
ChEBI
ChEMBL
Properties
Chemical Formula
Molar Mass
Appearance
Density
Melting Point
Boiling Point
Hazards
GHS Pictograms	[[File:|50px]]
GHS Signal Word
GHS Hazard Statements
NFPA 704	[[File:|50px]]
References

Resminostat (4SC-201 or RAS2410) is an orally bioavailable inhibitor of histone deacetylases (HDACs), of which inhibitors are antineoplastic agents.<ref>

Biological activity of resminostat in selleck chemicals research(link). {{{website}}}. selleck.

</ref>
In 2011, the German drug maker 4SC was granted orphan drug designation for resminostat by the US FDA for the treatment of hepatocellular carcinoma (HCC).<ref>

4SC's Anti-Cancer Drug Resminostat achieves Median Overall Survival of 8.0 Months in Second-Line Advanced Liver Cancer (HCC) Patients(link). {{{website}}}.

September 2012.

</ref>

In 2016 the FDA granted [another?] IND for clinical tests in combination with sorafenib for HCC.<ref name=IND-2016>4SC AG: FDA approves IND application for resminostat in liver cancer. Feb 2016</ref> 4SC say "In several phase I and phase II trials, resminostat has already demonstrated very good safety and tolerability, alongside promising indications of efficacy."<ref name=IND-2016/>

Clinical trials

It has undergone a phase I/II clinical trial for K-ras mutated advanced colorectal carcinoma.<ref>4SC-201 (Resminostat) in Advanced Colorectal Carcinoma (SHORE)</ref>

It has undergone a phase II clinical trial for relapsed or refractory Hodgkin's Lymphoma.<ref>Resminostat (4SC-201) in Relapsed or Refractory Hodgkin's Lymphoma (SAPHIRE)</ref>

Mechanism

Resminostat restrains the phosphorylation of 4E-BP1 and p70S6k, indicating an disturbance with Akt signalling pathway. The treatment of resminostat leads to a drop of Bim and Bax protein level and Bcl-xL level.<ref>,

 First-in-human, pharmacokinetic and pharmacodynamic phase I study of Resminostat, an oral histone deacetylase inhibitor, in patients with advanced solid tumors., 
 , 
 
 Vol. 19(Issue: 19),
 pp. 5494–504,
 DOI: 10.1158/1078-0432.CCR-13-0735,
 
 PMC: 3790647,</ref>

As with other HDAC inhibitors such as pracinostat, the inhibition of HDACs by resminostat results in an accumulation of highly acetylated histones, followed by an abduction of chromatin remodeling, inhibition of tumor suppressor genes transcription and cell division, and finally tumor cell apoptosis.